[Effect of the beta-receptor blockers propranolol and tilinolol on glucose- orciprenaline-induced insulin secretion, glucose tolerance and the behavior of non-esterified free fatty acids in metabolically healthy subjects].
The therapeutic blocking f beta-receptors is not restricted to the cardiovascular system, bronchial musculature and lipolysis, but concerns all sympathetically innerved organs and sympathetically moduled processes in the human organism. The effect of the beta-blockers also depends upon the numerical relation of beta 1 : beta 2-receptors, which is typical for the individual organs. Since the beta 1-receptors prevail in the human myocardium and the catecholamine-induce lipolysis is also realized above all through the beta 1-receptors, the blocking of beta 1-receptors fulfils the therapeutic aim to block the increase of heart rate and free fatty acids undesired under load and on account of the less specific side effects it is to be preferred to the more comprehensive beta 1-blocking in the long-term therapy of cardiovascular diseases. In diseases of the heart in rest and under load above all the noradrenalin-serum-concentration is increased (NA = alpha-beta 1-stimulator), a prevalent blocking of beta 1-receptors justifies the above mentioned therapeutical aim in these patients. It is referred to different effects of the beta 1-selective blockers in comparison to the beta 1-beta 2-blockers in the carbohydrate, fatty and electrolyte metabolism as well as in the secretion of various hormones. The further examination and the therapeutical consideration of the haemodynamic, metabolic and hormonal effects of the beta 1-blockers and their differences of effect are suitable further to qualify the therapy with beta-blockers.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D005230:Fatty Acids, Nonesterified / Q000378:metabolism*; D005951:Glucose Tolerance Test; D006019:Glycolysis / Q000187:drug effects; D006801:Humans; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008066:Lipolysis / Q000187:drug effects; D009921:Metaproterenol / Q000494:pharmacology; D010179:Pancreas / Q000187:drug effects*
D000319:Adrenergic beta-Antagonists; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D009921:Metaproterenol
Der Einfluss der beta-Rezeptorenblocker Propranolol und Talinolol auf die glukose- orziprenalininduzierte Insulinsekretin, die Glukosetoleranz und das Werhalten der unveresterten freinen Fettsäuren bei stoffwechselgesunden Probanden.